Today: 28 December 2025
Subscribe
Browse Category

Oncology News 17 July 2025 - 15 December 2025

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

(SEO): Johnson & Johnson (NYSE: JNJ) climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3 Johnson & Johnson stock (NYSE: JNJ) capped a volatile but decisively positive week by closing
13 December 2025
 ·  ·  ·  ·  · 
Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh
11 December 2025
 ·  ·  ·  ·  · 
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in
17 November 2025
 ·  ·  ·  · 
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on
17 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS)
10 November 2025
 ·  ·  ·  ·  · 
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

In April 2025, Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation. The device pairs an immunohistochemistry stain for TROP2 with a digital pathology AI algorithm that runs in Roche’s Navify system
17 July 2025
 ·  ·  ·  ·  ·  · 
Go toTop